Richards, Nathan G <br/><br/>
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.  [electronic resource] 

 -  Annals of surgery  Sep 2010 
 - 499-505; discussion 505-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-1140 
<br/><br/><label>Standard No.: </label>10.1097/SLA.0b013e3181f1fd44  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Biomarkers, Tumor--metabolism<br/>Combined Modality Therapy<br/>Cyclooxygenase 2--metabolism<br/>Deoxycytidine--analogs & derivatives<br/>ELAV Proteins--metabolism<br/>ELAV-Like Protein 2<br/>Female<br/>Humans<br/>Immunoenzyme Techniques<br/>Male<br/>Microarray Analysis<br/>Neoplasm Staging<br/>Pancreatic Neoplasms--drug therapy<br/>Prognosis<br/>Proportional Hazards Models<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Survival Analysis<br/>Vascular Endothelial Growth Factor A--metabolism<br/>Gemcitabine